Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 13, 2023
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
James Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.
The American Journal of Surgical Pathology
|
March 27, 2003
Papillary tumor of the pineal region
Anne Jouvet, François Fauchon, Pawel Liberski, et al.
EJNMMI Research
|
July 1, 2020
Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader
Laurent Besret, Sébastien d'Heilly, Cathy Aubert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 17, 2009
Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice
Min Wu, Lina Jung, Adrian B Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2022
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
José Á García-Sáenz, Noelia Martínez-Jáñez, Ricardo Cubedo, et al.
Gynecologic Oncology
|
October 15, 2023
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
Sileny N Han, Amit Oza, Nicoletta Colombo, et al.
Clinical Lung Cancer
|
June 29, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Lyudmila Bazhenova, J G Hodgson, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Bora Lim, David A Potter, Mohamad A Salkeni, et al.
JAMA Oncology
|
October 14, 2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
Caicun Zhou, Suresh S Ramalingam, Tae Min Kim, et al.
Cancer Discovery
|
February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J Riely, Joel W Neal, D Ross Camidge, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 13, 2023
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
James Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.
The American Journal of Surgical Pathology
|
March 27, 2003
Papillary tumor of the pineal region
Anne Jouvet, François Fauchon, Pawel Liberski, et al.
EJNMMI Research
|
July 1, 2020
Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader
Laurent Besret, Sébastien d'Heilly, Cathy Aubert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 17, 2009
Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice
Min Wu, Lina Jung, Adrian B Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2022
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
José Á García-Sáenz, Noelia Martínez-Jáñez, Ricardo Cubedo, et al.
Gynecologic Oncology
|
October 15, 2023
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
Sileny N Han, Amit Oza, Nicoletta Colombo, et al.
Clinical Lung Cancer
|
June 29, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Lyudmila Bazhenova, J G Hodgson, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Bora Lim, David A Potter, Mohamad A Salkeni, et al.
JAMA Oncology
|
October 14, 2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
Caicun Zhou, Suresh S Ramalingam, Tae Min Kim, et al.
Cancer Discovery
|
February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J Riely, Joel W Neal, D Ross Camidge, et al.
Page
of 4